(FNJN) Participation in Open Register of Patent Ownership

(FCSC) Announces Pricing of Public Offering of Common Stock

EXTON, Pa., July 22, 2015  — Fibrocell Science, Inc., (NASDAQ:FCSC), an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet needs, today announced the pricing of an underwritten public offering of 2.6 million shares of its common stock at a price of $5.80 per share. In addition, Fibrocell has granted the underwriters a 30-day option to purchase up to an additional 0.4 million shares of common stock.

All shares in the offering are being sold by Fibrocell, with expected net proceeds to Fibrocell of approximately $13.6 million, after deducting underwriting discounts and commissions and estimated offering expenses and not including any proceeds to be received by Fibrocell if the underwriters were to exercise the 30-day option. The offering is expected to close on or about July 27, 2015, subject to satisfaction of customary closing conditions.

Fibrocell intends to use the net proceeds of the offering for the continued clinical and preclinical development of its product candidates and for other general corporate purposes.

Wells Fargo Securities, LLC is acting as sole book-running manager and representative of the underwriters for the offering. Roth Capital Partners and Griffin Securities are acting as co-managers for the offering.

The offering is being made by Fibrocell pursuant to a shelf registration statement on Form S-3 previously filed with the Securities and Exchange Commission (SEC), which the SEC declared effective on August 28, 2013. A final prospectus supplement related to the offering will be filed with the SEC and will be available on the website of the SEC at www.sec.gov. Copies of the final prospectus supplement may also be obtained, when available, from Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 375 Park Avenue, 4th Floor, New York, NY 10152, by email at cmclientsupport@wellsfargo.com, or by calling 1-800-326-5897.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

About Fibrocell Science, Inc.

Fibrocell is an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell’s most advanced product candidate, azficel-T, uses its proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of chronic dysphonia resulting from vocal cord scarring. In collaboration with Intrexon Corporation, a leader in synthetic biology, Fibrocell is also developing gene therapies for skin diseases using gene-modified autologous fibroblasts. Fibrocell has submitted an IND application to the FDA for FCX-007, its lead orphan gene-therapy product candidate, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Fibrocell is in pre-clinical development of FCX-013, its second gene-therapy product candidate, for the treatment of linear scleroderma.

Forward-Looking Statements

This press release contains, and our officers and representatives may from time to time make, statements that are “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to a variety of matters, including, without limitation, Fibrocell’s expectations regarding the completion, timing and size of the proposed public offering, Fibrocell’s anticipated proceeds from the offering and its use of those proceeds and other statements that are not purely statements of historical fact.

These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of Fibrocell’s control. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others: varying interpretation of research data; the outcome of regulatory review of the IND; uncertainties relating to the initiation and completion of clinical trials; and whether clinical trial results will validate and support the safety and efficacy of our product candidates, as well as those set forth under the caption “Item 1A. Risk Factors” in Fibrocell’s most recent Form 10-K filing.

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. In addition, Fibrocell operates in a highly competitive and rapidly changing environment, and new risks may arise. Accordingly, you should not place any reliance on forward-looking statements as a prediction of actual results. Fibrocell disclaims any intention to, and undertakes no obligation to, update or revise any forward-looking statement. You are also urged to carefully review and consider the various disclosures in Fibrocell’s most recent annual report on Form 10-K, our most recent Form 10-Q as well as other public filings with the SEC since the filing of Fibrocell’s most recent annual report.

CONTACT: Investor Contact:
         Karen Casey
         Fibrocell
         Tel: +1 (484) 713-6133
         kcasey@fibrocellscience.com

(VALU) FY Earnings of $0.74 Per Share, up 7.7% from Prior Fiscal Year

Value Line, Inc., (NASDAQ: VALU) reports results for the fiscal year ended April 30, 2015.

During the twelve months ended April 30, 2015, the Company’s net income of $7,292,000, or $0.74 per share, was $524,000 or 7.7% above net income of $6,768,000, or $0.69 per share, for the twelve months ended April 30, 2014. During the twelve months ended April 30, 2015 there were 9,813,623 average common shares outstanding as compared to 9,839,155 average common shares outstanding during the twelve months ended April 30, 2014. Income from operations of $2,399,000 for the twelve months ended April 30, 2015 which included additional depreciation and amortization expense of $630,000 including accelerated amortization of $138,000 related to obsolete software recorded in the fourth quarter of fiscal 2015 was $102,000 below income from operations of $2,501,000 for the twelve months ended April 30, 2014. During the fourth quarter ended April 30, 2015, the Company’s reported loss from operations of $560,000 was the result of 12 weeks of print revenues recorded in the fourth quarter of fiscal 2015 as compared to 13 weeks recorded in the fourth quarter of fiscal 2014, an additional direct marketing campaign in the fourth quarter of fiscal 2015, and the accelerated write-off of obsolete software. Total product line circulation at April 30, 2015 was 5.8% above total product line circulation at April 30, 2014, continuing a positive trend of increased subscribers with the product mix including increased sales of our introductory-level services. The Company has been successful in growing revenues from digitally-delivered investment periodicals within the institutional area and in our consumer-oriented introductory offerings. Institutional Sales total sales orders for the twelve months ended April 30, 2015 were $481,000 or 3.7%, above comparable total sales orders for the twelve months ended April 30, 2014.

Shareholders’ equity of $34,439,000 at April 30, 2015 compares favorably to shareholders’ equity of $33,298,000 at April 30, 2014. As of April 30, 2015, retained earnings and liquid assets were $34,587,000 and $15,506,000, respectively.

The Company recently announced a 6.7% increase in its quarterly dividend from $0.15 per common share to $0.16 per common share and the Board of Directors re-affirmed the Company’s Common Stock Repurchase program.

The Company’s annual report on Form 10-K has been filed with the SEC and is available on the Company’s website at www.valueline.com/About/corporate_filings.aspx. Shareholders may receive a printed copy, free of charge upon request.

Value Line, Inc. is a leading New York based provider of investment research. The Value Line Investment Survey is one of the most widely used sources of independent equity investment research. Value Line also publishes a range of proprietary investment research in both print and digital formats including research in the areas of Mutual Funds, Options and Convertible securities. Value Line’s acclaimed research also enables the Company to provide specialized products such as Value Line Select, Value Line Special Situations, Value Line Select: Dividend Income & Growth, and copyright data, distributed under copyright agreements for fees, including certain proprietary ranking system information and other proprietary information used in third party products. Investment Management services are provided through its substantial non-controlling and non-voting interests in EULAV Asset Management, the investment advisor to The Value Line Family of Mutual Funds. Value Line’s products are available to individual investors by mail, at www.valueline.com or through 1-800-VALUELINE or 1-800-535-9648, while institutional-level services for professional investors, advisers, corporate, academic, municipal and legal libraries are offered at www.ValueLinePro.com and at 1-800-531-1425.

Cautionary Statement Regarding Forward-Looking Information

This report contains statements that are predictive in nature, depend upon or refer to future events or conditions (including certain projections and business trends) accompanied by such phrases as “believe”, “estimate”, “expect”, “anticipate”, “will”, “intend” and other similar or negative expressions, that are “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995, as amended. Actual results for Value Line, Inc. (“Value Line” or “the Company”) may differ materially from those projected as a result of certain risks and uncertainties, including but not limited to the following:

• maintaining revenue from subscriptions for the Company’s digital and print published products;
• changes in market and economic conditions, including global financial issues;
• protection of intellectual property rights;
• dependence on non-voting revenues and non-voting profits interests in EULAV Asset Management, a Delaware statutory trust (“EAM” or “EAM Trust”), which serves as the investment advisor to the Value Line Funds and engages in related distribution, marketing and administrative services;
• fluctuations in EAM’s assets under management due to broadly based changes in the values of equity and debt securities, redemptions by investors and other factors, and the effect these changes may have on the valuation of EAM’s intangible assets;
• dependence on key personnel;
• competition in the fields of publishing, copyright data and investment management;
• the impact of government regulation on the Company’s and EAM’s businesses;
• availability of free or low cost investment data through discount brokers or generally over the internet;
• terrorist attacks, cyber security attacks and natural disasters;
• other risks and uncertainties, including but not limited to the risks described in Item 1A, “Risk Factors” of the Company’s Annual Report on Form 10-K for the year ended April 30, 2015; and

• other risks and uncertainties arising from time to time.

These factors are not necessarily all of the important factors that could cause actual results to differ materially from those expressed in any of our forward-looking statements. Other unknown or unpredictable factors which may involve external factors over which we may have no control or changes in our plans, strategies, objectives, expectations or intentions, which may happen at any time at our discretion, could also have material adverse effects on future results. Except as otherwise required to be disclosed in periodic reports required to be filed by public companies with the SEC pursuant to the SEC’s rules, we have no duty to update these statements, and we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. In light of these risks and uncertainties, current plans, anticipated actions, and future financial conditions and results may differ from those expressed in any forward-looking information contained herein.

(BZUN) Signs Cooperation Agreement With Alibaba Group’s Logistics Arm Cainiao

SHANGHAI, China, July 22, 2015  — Baozun Inc. (Nasdaq:BZUN) (“Baozun” or the “Company”), the leading brand e-commerce solutions provider in China, today announced that the Company has signed a cooperation agreement with Alibaba Group Holding Limited’s (“Alibaba”) (NYSE:BABA) logistics arm Cainiao Network Technology Co., Ltd. (“Cainiao”). The agreement is part of the Company’s plan to strengthen its logistics network in southern China by opening its sixth and newest logistics warehouse (“Guangzhou warehouse”) in Guangzhou’s Alibaba Cainiao Logistics Park.

Cainiao was founded in 2013 by Alibaba and a consortium of logistics companies in China. Cainiao operates a proprietary logistics platform that links third-party warehouses and distribution centers with logistics providers in order to enable greater efficiency across the entire delivery process. Cainiao’s platform plugs directly into the back-end of numerous e-commerce platforms, allowing each party to share and integrate confidential information on orders, inventory levels and delivery status.

According to the terms of the agreement, Baozun’s Guangzhou warehouse will sync directly with Cainiao’s platform, allowing the Company to improve the experience for both its brand e-commerce partners and buyers by closely monitoring and improving each step of the fulfillment process.

Mr. Vincent Qiu, Baozun’s CEO, commented, “With the signing of this agreement, we will be able to use Cainiao’s platform to provide our brand partners with better overall e-commerce logistics. By leveraging on our Guangzhou warehouse’s geographical location and Cainiao’s platform, we will be able to reduce transportation costs and inventory levels, shorten delivery times, and increase overall efficiency across southern China. Improving our logistical capabilities through agreements with platforms such as Cainiao’s directly supports our long-term growth by providing our clients with a better overall e-commerce solution.”

Safe Harbor Statements

This news release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “target,” “going forward,” “outlook” and similar statements. Such statements are based upon management’s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company’s control, which may cause the Company’s actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the U.S. Securities and Exchange Commission. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.

About Baozun Inc.

Baozun is the leading brand e-commerce solutions provider in China that helps brand partners execute their e-commerce strategies. The Company’s integrated capabilities encompass all aspects of the e-commerce value chain, covering IT solutions, store operations, digital marketing, customer services, warehousing and fulfillment. With e-commerce in China growing rapidly in both scale and complexity, brands look to Baozun as a trusted partner and rely on its local knowledge and industry expertise to execute their e-commerce strategies.

For more information, please visit http://ir.baozun.com

CONTACT: For investor and media inquiries, please contact:

         Baozun Inc.
         ir@baozun.com

         Christensen
         In China
         Mr. Christian Arnell
         Phone: +86-10-5900-1548
         E-mail: carnell@christensenir.com

         In US
         Ms. Linda Bergkamp
         Phone: +1-480-614-3004
         Email: lbergkamp@ChristensenIR.com

(ADK) Enters Into Agreements for All 40 Facilities; Sublease Remaining Properties

ATLANTA, July 21, 2015  — AdCare Health Systems, Inc. (NYSE MKT: ADK) (NYSE MKT: ADK.PRA), a self-managed healthcare real estate investment company that invests primarily in real estate purposed for senior living and long-term healthcare, today announced that it has reached an important milestone in its strategic transition to a property holding and leasing company. AdCare has entered into agreements for all 40 of its facilities.

• On July 20, 2015, AdCare signed an agreement to sublease two Georgia facilities to affiliates of Wellington Health Services L.L.C. Affiliates of Wellington currently sublease two of AdCare’s facilities. The sublease agreement for the two additional facilities represents initial year cash rent of $2.0 million, which is subject to an annual escalator of approximately 3%. The initial term of the sublease agreement is ten years with two renewal options, subject to renewal of the master lease under which AdCare leases the facilities. The transfer of operations under the sublease agreement is scheduled to be completed in the third quarter of 2015, subject to the receipt of landlord consent, required licenses and other state regulatory approvals. AdCare expects initial year cash rent, net of initial year cash rent expense, to be approximately $0.2 million.
• On July 17, 2015, AdCare signed an agreement to sublease one Arkansas facility to an affiliate of Aria Health Group, LLC. Affiliates of Aria currently sublease eight of AdCare’s facilities. The sublease agreement has a seven-year initial term, with a 3% per annum escalator and a five-year renewal option and represents initial year cash rent of $600,000. The transfer of operations under the sublease agreement is scheduled to be completed in the third quarter of 2015, subject to the receipt of required licenses and other state regulatory approvals.

“Today is an important milestone in the Company’s strategic transition. By entering into agreements on these three facilities, we have now executed agreements to lease, manage, or sell all 40 of our facilities,” commented Bill McBride, AdCare’s Chairman and Chief Executive Officer. “Already, 24 facilities have completed the operations transfer to third party operators, with additional facilities scheduled to transition within the next 90 days as other approvals are received.”

“I am encouraged with our progress to date, and as we remain focused on diligently transitioning operations to third party operators, we are simultaneously identifying attractive property acquisition opportunities for growth,” continued Mr. McBride. “We have a growing pipeline that we are actively evaluating to put capital to work and increase shareholder value. Our progress to date gave the Board of Directors confidence to increase the dividend on our common stock by 10%, as we recently announced, reaffirming our commitment to return cash to our shareholders as we execute our business plan.”

Since the Board of Directors approved the strategic plan to transition AdCare’s business from an owner and operator of healthcare facilities to a healthcare property holding and leasing company, AdCare has entered into agreements for all 40 of its healthcare facilities. Of these 40 healthcare facilities:

• Twenty-seven facilities have transferred operations to third-party operators or are under a management contract with an indefinite term;
• One facility in Arkansas has been sold;
• Of the remaining 12 facilities pending transfer:
  • Of the five facilities in Ohio, AdCare has received HUD approval on four, and one facility does not require HUD approval. AdCare expects to transfer operations to a third-party operator for these five facilities on August 1, 2015;
  • The transfer of two facilities in Georgia is expected to occur in the third quarter of 2015, subject to receipt of landlord consent, required licenses and other state regulatory approvals;
  • AdCare expects to transition one facility in Arkansas to a third-party operator in the third quarter of 2015, subject to receipt of required licenses and other state regulatory approvals;
  • AdCare expects to transition two facilities in Oklahoma to a third-party operator during the third quarter of 2015, subject to receipt of required licenses;
  • The transfer of one facility in Georgia is subject to HUD approval and is expected to occur in the third quarter of 2015; and
  • AdCare expects to close the sale of one facility in Oklahoma in the third quarter, subject to certain termination provisions and closing conditions.

About AdCare Health Systems

AdCare Health Systems, Inc. (NYSE MKT: ADK) (NYSE MKT: ADK.PRA) is a self-managed healthcare real estate investment company that invests primarily in real estate purposed for senior living and long-term healthcare through facility lease and sub-lease transactions. The Company currently owns, leases or manages for third parties 39 facilities, primarily in the Southeast. For more information about AdCare, visit www.adcarehealth.com.

Important Cautions Regarding Forward-Looking Statements

Statements contained in this press release that are not historical facts may be forward-looking statements within the meaning of federal law. Such statements can be identified by the use of forward-looking terminology, such as “believes,” “expects,” “plans,” “intends,” “anticipates” and variations of such words or similar expressions, but their absence does not mean that the statement is not forward-looking. Statements in this press release that are forward-looking include, among other things, statements regarding the Company’s transition to a healthcare facilities holding and leasing company, statements regarding the transfer of operations to third party operators, statements regarding acquisition opportunities, and statements regarding any dividend. Such forward-looking statements reflect management’s beliefs and assumptions and are based upon information currently available to management and involve known and unknown risks, results, performance or achievements of AdCare, which may differ materially from those expressed or implied in such statements. Such factors are identified in the public filings made by AdCare with the Securities and Exchange Commission, including AdCare’s Annual Report on Form 10-K for the year ended December 31, 2014. There is no assurance that such factors or other factors will not affect the accuracy of such forward-looking statements. Except where required by law, AdCare undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

References to the consolidated company and its assets and activities, as well as the use of terms such as “we,” “us,” “our,” and similar verbiage, is not meant to imply that AdCare Health Systems, Inc. has direct operating assets, employees or revenue or that any of the facilities, the home health business or other related businesses are operated by the same entity.

(MSON) BoneScalpel™ Workshop Draws More Than 70 Surgeons At IMAST Meeting

FARMINGDALE, N.Y., July 21, 2015  — Misonix, Inc. (NASDAQ: MSON), an international ultrasonic surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic instruments for spine surgery, neurosurgery and other surgical specialties, hosted a successful BoneScalpel Hands-On Workshop during the International Meeting on Advanced Spine Technologies (“IMAST”) in Kuala Lumpur, Malaysia last week.  More than 70 surgeons attended the workshop and were trained on advanced spine surgical techniques utilizing the BoneScalpel.

“We are extremely pleased to see this degree of interest from international spine surgeons.  The key opinion leaders that presented at this year’s workshop focused on the clinical benefits of using the BoneScalpel and prepared the workshop attendees for future use in their own practices.  Training this many surgeons at one event is an exciting way to kick off our new fiscal year,” said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix.

The Ultrasonics in Spine Surgery: BoneScalpel Hands-On Workshop was moderated and facilitated by the following group of leading spine surgeons:

• Dr. Peter Newton, Rady Children’s Hospital in San Diego, CA;
• Dr. Juan Uribe, University of South Florida in Tampa, FL; and
• Dr. Greg Mundis, Scripps Memorial Hospital in La Jolla, CA.

The surgeon presenters discussed their surgical techniques and clinical evidence on the application of the BoneScalpel in Minimally-Invasive Spine Surgery, AIS Posterior Release, Cervical Laminoplasty and other degenerative procedures.

The faculty agreed that the use of the BoneScalpel leads to a safer, more efficient surgical experience with repeatable reduction in blood loss and an increase in the amount of viable autogenous bone graft harvested. Dr. Juan Uribe commented on his experience in adopting the technology, “I was immediately enthused by the added safety offered by the BoneScalpel when cutting bone near the dura and nerves.  In my minimally-invasive, transforaminal lumbar interbody fusion (tlif) procedures, I have achieved surgical efficiencies, safer facectomies, less blood loss and more viable autograft bone.”

Dr. Greg Mundis explained, “Adding the BoneScalpel to my procedures has positively impacted my surgical practice.  For example, when I perform a deformity correction, my patients will now lose less blood, need fewer transfusions and go to the recovery room faster than they had in the past.”

“It was easy to recognize the clinical value that the BoneScalpel brings to spine surgery within the first few cases of using it.  It allows me to remove bone safely and reduce blood loss.  We now use it in every deformity procedure,” concluded Dr. Peter Newton.

The IMAST meeting is a three-day international forum with leading spine surgeons discussing and demonstrating innovative surgical technologies that help improve patient care. This year’s meeting was attended by over 775 delegates.

About Misonix

Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix’s therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $1.5 billion annually; Misonix’s proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company’s Web site at www.misonix.com.

Safe Harbor Statement

With the exception of historical information contained in this press release, content herein may contain “forward looking statements” that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company’s business lines, and other factors discussed in the Company’s Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

(SYN) Announces Closing of Recent Equity Offering

ROCKVILLE, Md., July 21, 2015  — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, today announced that it has closed the public offering of 15.3 million shares of common stock, including the fully exercised over-allotment option by the underwriters covering 2.0 million shares, at an offering price of $3.00 per share. The total gross proceeds of the offering, including the exercise in full of the over-allotment option, were approximately $46.0 million. Net proceeds to the Company, after deducting the underwriters’ discount and other estimated expenses, are expected to be approximately $42.6 million.

The Company anticipates using the net proceeds from the offering to fund its clinical programs including Phase 2 clinical candidates, SYN-004 for the prevention of C. difficile and SYN-010 for the treatment of irritable bowel syndrome with constipation (IBS-C), research & development, potential licensing and acquisition of intellectual property, investments in and acquisition of complementary businesses or partnerships, and for general corporate purposes.

William Blair & Company, L.L.C. and RBC Capital Markets, L.L.C. are the joint book-running managers for the offering. BTIG, LLC is serving as co-manager for the offering.

A preliminary prospectus supplement and a final prospectus supplement relating to these securities have been filed with the SEC and are available at the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and the final prospectus supplement may also be obtained from William Blair & Company, L.L.C., Attention: Prospectus Department, 222 West Adams Street, Chicago, Illinois 60606, by telephone at (800) 621-0687, or by email at prospectus@williamblair.com. RBC Capital Markets, L.L.C., Attention: Equity Syndicate, 200 Vesey Street, 8^th Floor, New York, NY 10281-8098, or by telephone at (877) 822-4098.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

About Synthetic Biologics, Inc.

Synthetic Biologics, Inc. (NYSE MKT: SYN) is a microbiome-focused, clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company’s lead candidates in Phase 2 development include SYN-004 which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD), and SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat the underlying cause of irritable bowel syndrome with constipation (IBS-C). In addition, the Company is developing a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS, and a monoclonal antibody combination for the treatment of Pertussis. For more information, please visit Synthetic Biologics’ website at www.syntheticbiologics.com.

This release includes forward-looking statements on Synthetic Biologics’ current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements with respect to this offering and the successful execution of the Company’s business strategy, including its intended use of proceeds. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from those reflected in Synthetic Biologics’ forward-looking statements include, among others, the additional clinical studies and results not meeting expectations, the inability to commence and complete clinical trials when anticipated and other factors described in Synthetic Biologics’ report on Form 10-K for the year ended December 31, 2014 and any other filings with the SEC. The information in this release is provided only as of the date of this release, and Synthetic Biologics undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

(CUI) Announces Additional IRIS® Purchase Order

TUALATIN, Ore., July 21, 2015  — CUI Global, Inc. (NASDAQ: CUI) announced today that its wholly-owned UK energy subsidiary, Orbital Gas Systems Ltd., has received approval from one of the UK’s largest pipeline operators to install and commission four of its previously purchased IRIS kiosks. Further, the company has received a purchase order from the same customer for additional IRIS kiosks to be produced at its UK facility for installation and commissioning later this year.

In addition, the company can confirm that several customers have now successfully completed testing of its other proprietary natural gas technologies, the GasPT® Analyzer and VE Technology®, and that it (the company) has received multiple purchase orders for those products.  These purchase orders come from several large energy producers/transporters in various geographic areas, including, but not limited to: a large North American gas transportation and compression company; a Fortune 100 energy company for projects in both Australia and North America; a major European gas transmission company; an Asian gas turbine manufacturer; and others.

CUI Global’s President & CEO, William Clough commented, “The commissioning of the previously purchased IRIS kiosks, along with the ordering of new kiosks demonstrates the efficiencies, control, and other benefits this exciting technology provides to the pipeline operator. This makes us even more confident regarding a larger deployment of the technology in the future. Meanwhile, over the past several months, we are beginning to see many of the tests in which our technologies have participated over the past weeks, months, and, in some cases, years, actually starting to ‘bear fruit’ in the form of purchase orders from some of the industry’s most iconic players.”

“While there is still much work to do, this transition from testing to sales demonstrates the value and viability of our energy technologies and bodes well for the company, its employees, and its shareholders,” Clough concluded.

About CUI Global, Inc.
Delivering Innovative Technologies for an Interconnected World . . . . .

CUI Global, Inc. is a publicly traded company dedicated to maximizing shareholder value through the acquisition and development of innovative companies, products and technologies. From Orbital Gas Systems’ advanced GasPT2 platform targeting the energy sector, to CUI Inc.’s digital power platform serving the networking and telecom space, CUI Global and its subsidiaries have built a diversified portfolio of industry leading technologies that touch many markets. As a publicly traded company, shareholders are able to participate in the opportunities, revenues, and profits generated by the products, technologies, and market channels of CUI Global and its subsidiaries. But most importantly, a commitment to conduct business with a high level of integrity, respect, and philanthropic dedication allows the organization to make a difference in the lives of their customers, employees, investors and global community.

For more information please visit www.cuiglobal.com

About Orbital Gas Systems Ltd.

Orbital Gas Systems Ltd (“Orbital-UK”) is the largest natural gas systems integrator in the United Kingdom. For over 30 years, Orbital-UK has developed its portfolio of products, services and resources to offer a diverse range of personalized gas engineering solutions to the gas utilities, power generation, emissions, manufacturing and automotive industries. Orbital-UK’s internationally recognized expertise in the natural gas industry, including bringing together the patented VE-technology with the ground-breaking GasPTi device, offers natural gas operators and users a comprehensive engineering array for the next generation of energy metering systems. Orbital-UK is a wholly owned subsidiary of CUI Global, Inc.

For more information, please visit www.orbital-uk.com or www.orbitalgassystems.com.

Important Cautions Regarding Forward Looking Statements
This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are subject to risks and uncertainties that could cause actual results to vary materially from those projected in the forward-looking statements. The company may experience significant fluctuations in future operating results due to a number of economic, competitive, and other factors, including, among other things, our reliance on third-party manufacturers and suppliers, government agency budgetary and political constraints, new or increased competition, changes in market demand, and the performance or reliability of our products. These factors and others could cause operating results to vary significantly from those in prior periods, and those projected in forward-looking statements. Additional information with respect to these and other factors, which could materially affect the company and its operations, are included in certain forms the company has filed with the Securities and Exchange Commission.

(UEC) Harry Anthony Elected President of Uranium Producers of America

SANTA FE, NM, July 21, 2015  – The Uranium Producers of America (UPA) announced today that Harry Anthony, a senior advisor with Uranium Energy Corp (UEC), has been elected as president of the national organization. The group, founded in 1985, works to promote a sustainable and strong domestic uranium mining and conversion industry by fostering free and fair competition.

Anthony, a resident of Kingsville, Texas, for almost 40 years, is a past Board Member and Chief Operating Officer of UEC, a publicly traded company based in Corpus Christi, Texas. The company is a leader in the field of uranium exploration, development and production. Mr. Anthony, an internationally recognized expert in the uranium industry, has been active in the energy arena for over 45 years and has been a Texas Registered Professional Engineer for over 35 years.

Amir Adnani, President and CEO of Uranium Energy Corp, said, “UEC has garnered tremendous benefit from Harry Anthony’s leadership and experience. With his service to UPA, the entire country will now benefit from his extensive knowledge of the uranium industry. We are pleased  that the UEC team continues to participate at the highest levels of the US uranium industry, including, among other appointments, our Executive VP Scott Melbye having earlier served as president of UPA.”

Prior to joining UEC, Mr. Anthony was a senior officer and director of Uranium Resources Inc.  During his 20-year tenure at URI, he was responsible for all technical aspects of mine development. He has also provided technical consulting services for many international energy production companies and is a sought-after speaker on uranium and related issues, having written and presented numerous reference papers on behalf of leading internationally recognized bodies including the International Atomic Energy Agency.

Mr. Anthony has a Bachelor’s and Master’s degree in Engineering Mechanics from Pennsylvania State University. He is the Past President of the Kingsville Chamber of Commerce, the Kingsville United Way, the Kingsville Rotary Club and the Kingsville Navy League.

Jon Indall, UPA’s Legal Counsel, said, “Harry Anthony is a proven leader in the uranium industry and we are grateful for his extensive experience. He understands that for the United States to become energy independent and for national security reasons, it is vital that domestic uranium serves as a prominent and stable component of our country’s nuclear fuel supply.”

About Uranium Producers of America

The Uranium Producers of America (“UPA”) was founded in 1985 to promote a sustainable and strong domestic uranium mining and conversion industry by fostering free and fair competition while being environmentally sensitive to the communities in which we live and work. UPA believes for the United States to become energy independent and for national security reasons, it is vital that domestic uranium serves as a prominent and stable component of our country’s nuclear fuel supply. Please go to www.theupa.org for more information on Uranium Producers of America.

About Uranium Energy Corp

Uranium Energy Corp is a U.S.-based uranium mining and exploration company. The Company’s fully-licensed Hobson processing plant is central to all of its projects in South Texas, including the Palangana in-situ recovery (ISR) mine, the permitted Goliad ISR project and the development-stage Burke Hollow ISR project. Additionally, the Company controls a pipeline of advanced-stage projects in Arizona, Colorado and Paraguay. The Company’s operations are managed by professionals with a recognized profile for excellence in their industry, a profile based on many decades of hands-on experience in the key facets of uranium exploration, development and mining. Please go to www.uraniumenergy.com for more information on Uranium Energy Corp.

Safe Harbor Statement

Except for the statements of historical fact contained herein, the information presented in this news release constitutes “forward-looking statements” as such term is used in applicable United States and Canadian laws.  Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.  Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this news release can be found in the Company’s filings with the Securities and Exchange Commission. For forward-looking statements in this news release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise. This press release shall not constitute an offer to sell or the solicitation of an offer to buy securities.

(NEOG) Reports Record Revenues And Earnings

LANSING, Mich., July 21, 2015  — Neogen Corporation (NASDAQ: NEOG) announced today that net income for the fourth quarter of its 2015 fiscal year, which ended May 31, increased 25% to $9,384,000, or $0.25 per fully diluted share, from $7,537,000, $0.20 per share, in fiscal 2014.

Neogen’s fourth quarter revenues were $78,611,000, a 17% increase over revenues from 2014’s final quarter. Neogen’s revenues for its 2015 fiscal year increased 14% to $283,074,000, up from $247,405,000 in the company’s previous fiscal year. On an organic basis, growth for the company was 14% for the quarter, and 8% for the full year. Net income for the 2015 fiscal year increased 19% from the previous year to $33,526,000, or $0.90 per share, compared to the prior year’s $0.76 per share. Revenues and net income for the fourth quarter, and the 2015 fiscal year, established new all-time highs for the 33-year-old company.

“We are pleased to report a strong finish to our 2015 fiscal year, and increased momentum as we begin our new fiscal year. In our fourth quarter, we exceeded our goal of producing double-digit organic growth for both our Food and Animal Safety segments,” said James Herbert, Neogen’s chief executive officer and chairman. “Neogen is uniquely positioned to grow and prosper by helping the world’s food producers and processors meet ever-increasing challenges — whether inside the farm gate, or anywhere along the processing and distribution chain.”

The fourth quarter was the 93rd of the past 98 quarters that Neogen reported revenue increases as compared with the previous year — including all consecutive quarters in the last 10 years.

“Neogen’s increasing momentum has been the result of creating and expanding opportunities in our diverse global markets through the introduction of new products and services, and improving our operational capabilities,” said Richard Calk, Neogen’s president and chief operating officer. “For example, with the recent development of our improved ATP hygiene monitor, AccuPoint^® Advanced, we significantly upgraded our manufacturing technology and now also have a better product.”

Neogen’s gross margin was 49.4% in its 2015 fiscal year, compared to 49.6% for fiscal 2014. Operating expenses grew by 9% in 2015, less than revenue growth of 14%. Operating income as a percentage of revenues was 18.8% in the current year, as compared to 17.5% in the company’s 2014 fiscal year.

“We were adversely impacted by currency fluctuations in the fiscal year, particularly the second half of the year, as the strength of the U.S. dollar resulted in comparatively lower values for the euro, the British pound, the Brazilian real, and the Mexican peso,” said Steve Quinlan, Neogen’s chief financial officer. “These currency fluctuations negatively impacted both our top and bottom lines in the 2015 fiscal year, making our financial results even more impressive. Neogen experienced a strong year of cash generation, and our inventory control efforts showed progress, as we held inventory levels essentially flat for the year as our revenues increased 14%.”

Revenues for the company’s Food Safety segment increased 13% during the fiscal year compared to the prior year. Sales of Neogen’s general microbiology products increased 40% in fiscal 2015 compared to the prior year, aided in large part by the Oct. 1, 2014 acquisition of BioLumix^®. The company believes there is a strong synergistic relationship between the BioLumix and Soleris^® test systems, as both systems allow for the accurate detection of spoilage organisms in much less time than traditional microbiology methods. Overall organic growth for the Food Safety segment was 10% for the year.

Sales of Neogen’s rapid tests for food allergens, such as gluten and peanuts, continued their strong performance in the fiscal year, growing approximately 18% compared to the prior year. The growth was aided by increasing global regulatory efforts and consumer demand to ensure products represented as being free of food allergens are correctly labeled. The increase was also due to Neogen’s effective response to the discovery of large-scale contamination of cumin, and other spice blends, with peanut and other known food allergens.

Neogen’s Animal Safety segment reported a revenue increase of 16% in its 2015 fiscal year when compared to 2014. The segment’s comparative increase was aided in part by three acquisitions made in the company’s 2014 fiscal year. Sales of the company’s rodenticides increased more than 20% in the current year compared to the prior year, as Neogen responded to a rodent outbreak in orchard crops throughout the northwest United States, and its products continue to make gains in the important global agricultural rodenticide market.

The Animal Safety segment also recorded a 29% increase in sales of its proprietary D3^® detectable veterinary needles compared to the 2014 fiscal year, and a 40% increase in sales of its drug residue tests for the forensic market. Sales of Neogen’s small animal supplements increased 23% in the current year when compared to the prior year, as the company responded to a market need for supplements used for thyroid hormone replacement therapy in dogs.

Revenues from the company’s worldwide veterinary genomic products and services increased approximately 27% in fiscal year 2015 compared to fiscal 2014. This increase resulted from growing acceptance of its proprietary genomic products, especially in Europe, new poultry business, and by the increased operational capacity gained from the move into larger and upgraded facilities early in the company’s 2015 fiscal year.

Revenues from Neogen’s Scotland-based subsidiary increased 11% for the 2015 fiscal year in local currencies, and 9% after converting to U.S. dollars, recording higher sales of mycotoxin test kits, genomics services, and several other key product lines. Neogen Latinoamerica’s sales increased 151%, mainly due to the transfer of Animal Safety customers in Central America, while Neogen do Brasil’s revenues decreased 3%, primarily due to currency translations. Following its Dec. 8, 2014, acquisition of its China-based distributor, Anapure, Neogen recorded a significant increase in sales into China, albeit from a small base. Anapure had been a distributor of Neogen’s food safety products for more than 10 years, and had also offered Neogen’s veterinary genomic services in recent years.

Neogen Corporation develops and markets products dedicated to food and animal safety. The company’s Food Safety Division markets dehydrated culture media and diagnostic test kits to detect foodborne bacteria, natural toxins, food allergens, drug residues, plant diseases and sanitation concerns. Neogen’s Animal Safety Division is a leader in the development of animal genomics along with the manufacturing and distribution of a variety of animal healthcare products, including diagnostics, pharmaceuticals, veterinary instruments, wound care and disinfectants.

Certain portions of this news release that do not relate to historical financial information constitute forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties. Actual future results and trends may differ materially from historical results or those expected depending on a variety of factors listed in Management’s Discussion and Analysis of Financial Condition and Results of Operations in the Company’s most recently filed Form 10-K.

(DSKX) Launches Spectral.Lash In Brazil’s Most Upscale Pharmacy Chain Drogaria Iguatemi

Pompano Beach, Fla., July 20, 2015  — DS Healthcare Group, Inc. (NASDAQ:DSKX), has launched its first campaign for its clinically proven eyelash stimulating product Spectral.Lash in Brazil’s Drogaria Iguatemi, the leading high-end retail drugstore chain in Sao Paulo and Rio de Janeiro, Brazil.

The campaign features Spectral.Lash in floor-to-ceiling displays throughout its premium high-traffic prestigious locations, showcases Spectral.Lash on the cover of its monthly magazine and features the product on the company’s home page. The campaign has marked the launch of the highly anticipated introduction of Spectral.Lash and has set sales records throughout key markets.

“The rollout of Spectral.Lash has blown away our greatest expectations. We believe this product will continue to drive considerable revenue going forward. This product alone could represent as much as 30% of sales in Brazil, given Brazilian’s obsession with their appearance” commented Leonardo Chiacchio CEO of DS Laboratories do Brasil. “We continue to increase our presence throughout Brazil’s leading pharmacy chains and expect to be present in over 1000 locations in the next 12 months” concluded Chiacchio.

Daniel Khesin, President and CEO of DS Healthcare added, “We expect Brazil to represent one of the largest growth drivers for DS Healthcare. With the Brazilian cosmetic market leading second only to the US in size it is an ideal market for our products”.

The Sao Paulo metropolitan area has a population of 20 million, in one of the fastest growing beauty markets in the world. According to a U.S. Department of Commerce report titled, Doing Business in Brazil, “Hair care products make up the largest segment of the Brazilian cosmetics and toiletries market. Shampoo sales, both imported and locally made, constitute about 50 percent of domestic sales; they are divided evenly between Brazilian and well-known multinational suppliers.”

Drogaria Iguatemi is Brazil’s most affluent chain of pharmacies. Selecting to carry only the most important brands in medicine, cosmetics, derma-cosmetics and skin care products in the world. http://www.drogariaiguatemi.com.br

In an independent clinical study, patients using Spectral.Lash, a cutting-edge treatment from DS Laboratories, resulted in 100% of users experiencing 25% thicker eyelashes within four weeks. Spectral.Lash deploys a breakthrough peptide complex, and scientists believe that peptides, composed of structural amino acids, work by stimulating the expression of keratin genes and by improving overall eyelid health. 

About DS Healthcare Group

DS Healthcare Group Inc. leads in the development of biotechnology for topical therapies. It markets through online and specialty retailers, distributors, cosmetics wholesalers, and salons. Its research has led to a highly innovative portfolio of personal care products and additional innovations in pharmaceutical projects. For more information on DS Health Group’s flagship brand, visit www.dslaboratories.com

Forward-looking statements

Except for statements of historical fact, the matters discussed in this press release are forward-looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies, and are generally preceded by words such as “future,” “plan” or “planned,” “expects,” or “projected.” These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company’s control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing and marketing products, intense competition, and additional risks factors as discussed in reports filed by the company with the Securities and Exchange Commission, which are available at http://www.sec.gov

Abner Silva
DS Healthcare Group
407.342.4112
Abner@DSHealthgroup.com

(GPRO) Unveils Its Premium Content Licensing Portal

SAN MATEO, Calif., July 20, 2015  — GoPro, Inc. (NASDAQ: GPRO), enabler of some of today’s most engaging content, today announces the next step in rewarding the GoPro creator community with the launch of a premium content licensing portal for global advertising brands and agencies to license premiere video and images. The high-end offering is all about inspiring creative professionals to use beautiful imagery, incredible stories, and rich data created by GoPro and GoPro creators. Above all, it’s yet another way for GoPro to reward its inspirational creator community.

The portal is unique in that it offers high production value content, all accessible from one source. It also eliminates the pain points creative professionals have when sourcing content by helping them clear copyrights and likeness rights, easy access to creators’ content and organized, efficient, time-saving tools to search, download and preview content to license for use in advertising, news and other media and entertainment.

Key features include:

Discovery

• Content Merchandising – showcasing new and popular content
• Search & Filtering – enhanced discovery based on rich meta-data
• Video Previews – at-a-glance video previews

Download

• Lightbox – video preview sharing tool for creative team members
• Downloads ability to download low and high resolution file formats with batch download functionality
• Watermarking – visual watermarks ensure that the use of pre-licensed content is secure

License Request Workflow

• Licensing – content licensing request workflow
• Access Control – only approved agencies will be permitted to access and license content
• Reporting – license request tracking and status reporting

If you are a creative professional and would like to request access, please visit the site to register.

About GoPro, Inc. (NASDAQ:GPRO) GoPro, Inc. is transforming the way people capture and share their lives. What began as an idea to help athletes self-document themselves engaged in their sport has become a widely adopted solution for people to capture themselves engaged in their interests, whatever they may be. From extreme to mainstream, professional to consumer, GoPro enables the world to capture and share its passion. And in turn, the world has helped GoPro become one of the most exciting and aspirational companies of our time.

For more information, visit www.gopro.com or connect with GoPro on YouTube, Twitter, Facebook, Pinterest, Instagram, or LinkedIn.

GOPRO® and HERO® are trademarks or registered trademarks of GoPro Inc. in the United States and other countries.

(BSTC) Approval of XIAFLEX® in Japan for the Treatment of Dupuytren’s Contracture

(SCON) Advances Development With SFCL Customers

Completes Qualification of Conductus Wire for Robinson’s Roebel Cable

AUSTIN, Texas, July 20, 2015  — Superconductor Technologies Inc. (STI) (Nasdaq:SCON), a world leader in the development and production of high temperature superconducting (HTS) materials and associated technologies, achieved positive results with multiple superconducting fault current limiter (SFCL) customers following the Conductus^® wire evaluation and testing completed in June and July 2015. The SFCL results demonstrated dramatic improvement compared to tests completed earlier. In addition, STI successfully completed qualification testing with the Robinson Research Institute at Victoria University of Wellington. Conductus wire is now approved for use in making Roebel cable, a winding cable, which is used in high-field magnets, transformers, utility-scale generators and large motors.

“As we rapidly approach final qualification, our customers are quickly providing detailed guidance that we believe will result in Conductus wire soon attaining all of the performance parameters required for SFCLs,” stated Jeff Quiram, STI’s president and chief executive officer. “We believe our SFCL customers have transitioned from a specification driven pass or fail testing methodology to a much more collaborative effort that involves business items such as forecasts, delivery lead times and price. Conductus wire is very close to passing all tests, and we are encouraged by our customers’ confidence that our wire will be qualified in the next few months. In parallel, we have initiated business discussions to ensure product availability matches demand.

“In conjunction with our partner, the Robinson Research Institute, we are engaged with multiple end use customers that plan to deploy Roebel cable in superconducting devices. With the successful qualification of Conductus for use in Robinson’s Roebel cable, we believe we are well positioned to continue to aggressively pursue numerous opportunities in Asia.”

Test Description

SFCL customers require Conductus wire to pass extensive engineering models and electrical testing that simulate characteristics of the wire performance in the SFCL device. The electrical tests replicate the thermal cycling of the superconducting wire in high-current operation. The latest results show that Conductus wire has made significant performance improvements in this area. Customers verified STI’s 550 Amp current handling performance and recognized that the mechanical properties of Conductus provide unsurpassed robustness. The goal of SFCL manufacturers is to standardize on high performance wire that will ensure they have the best in class product to protect the grid in a majority of existing substations.

About Superconductor Technologies Inc. (STI)

Superconductor Technologies Inc. is a global leader in superconducting innovation. Its Conductus^® superconducting wire platform offers high performance, cost-effective and scalable superconducting wire. With 100 times the current carrying capacity of conventional copper and aluminum, superconducting wire offers zero resistance with extreme high current density. This provides a significant benefit for electric power transmission and also enables much smaller or more powerful magnets for motors, generators, energy storage and medical equipment. Since 1987, STI has led innovation in HTS materials, developing more than 100 patents as well as proprietary trade secrets and manufacturing expertise. For more than 20 years STI utilized its unique HTS manufacturing process for solutions to maximize capacity utilization and coverage for Tier 1 telecommunications operators. Headquartered in Austin, TX, Superconductor Technologies Inc.’s common stock is listed on the NASDAQ Capital Market under the ticker symbol “SCON.” For more information about STI, please visit http://www.suptech.com.

Safe Harbor Statement 

Statements in this press release regarding our business that are not historical facts are “forward-looking statements” that involve risks and uncertainties. Forward-looking statements are not guarantees of future performance and are inherently subject to uncertainties and other factors, which could cause actual results to differ materially from the forward-looking statements. These factors and uncertainties include, but are not limited to: our limited cash and a history of losses; our need to materially grow our revenues from commercial operations and/or to raise additional capital (which financing may not be available on acceptable terms or at all) in the very near future, before cash reserves are depleted (which reserves are expected to be sufficient into the fourth quarter of 2015), to implement our current business plan and maintain our viability; and the performance and use of our equipment to produce wire in accordance with our timetable; overcoming technical challenges in attaining milestones to develop and manufacture commercial lengths of our HTS wire; the possibility of delays in customer evaluation and acceptance of our HTS wire; the limited number of potential customers; the limited number of suppliers for some of our components and our HTS wire; there being no significant backlog from quarter to quarter; our market being characterized by rapidly advancing technology; the impact of competitive products, technologies and pricing; manufacturing capacity constraints and difficulties; our ability to raise sufficient capital to fund our operations (whether through registered direct offerings or otherwise), and the impact on our strategic wire initiative of any inability to raise such funds; the impact of any financing activity on the level of our stock price, which may decline in connection with the sales under registered direct offerings or otherwise; the dilutive impact of any issuances of securities to raise capital; and local, regional, and national and international economic conditions and events and the impact they may have on us and our customers.

Forward-looking statements can be affected by many other factors, including, those described in the “Business” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of STI’s Annual Report on Form 10-K for the year ended December 31, 2014 and in STI’s other public filings. These documents are available online at STI’s website, www.suptech.com, or through the SEC’s website, www.sec.gov. Forward-looking statements are based on information presently available to senior management, and STI has not assumed any duty to update any forward-looking statements.

Investor Relations Contact
Cathy Mattison or Kirsten Chapman
LHA      +1-415-433-3777       invest@suptech.com

(EXEL) Positive Top-Line Results from METEOR Phase 3 Trial of Cabozantinib

The trial met its primary endpoint of demonstrating a statistically significant increase in progression-free survival (PFS) in the first 375 randomized patients as determined by an independent radiology committee (IRC). Cabozantinib reduced the risk of disease progression or death by 42 percent compared to the everolimus arm (hazard ratio [HR]=0.58, 95 percent CI 0.45-0.75, p<0.0001).

Data pertaining to overall survival (OS) in the entire study population of 658 patients, a secondary endpoint of the trial, were immature at the data cutoff. A prespecified interim analysis, triggered by the primary analysis for PFS, showed a trend in OS favoring cabozantinib (HR = 0.67, unadjusted 95 percent CI 0.51 – 0.89; p=0.005). At the time of the interim analysis, the pre-specified p-value of 0.0019 to achieve statistical significance was not reached. The trial will continue to the final analysis of OS anticipated in 2016.

METEOR’s primary analysis included a review of serious adverse event (SAE) data. Based on this analysis, the frequency of SAEs of any Grade regardless of causality was approximately balanced between study arms. The rate of treatment discontinuation due to adverse events was low (10%) in both study arms.

Detailed results of the trial will be submitted for presentation at an upcoming medical conference.

In April 2015, cabozantinib received Fast Track designation by the U.S. Food and Drug Administration (FDA) for the potential treatment of advanced RCC patients who have received one prior therapy. Based on the outcome of METEOR, Exelixis plans to complete regulatory filings in the United States and European Union in early 2016.

“We are eager to offer new treatment options for patients with metastatic RCC, particularly in the second-line setting where the most commonly utilized therapies have demonstrated a uniformly modest progression-free survival benefit,” said Toni K. Choueiri, M.D., clinical director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, and METEOR’s principal investigator. “The magnitude of the improvement in PFS observed with cabozantinib compared to everolimus in the METEOR trial is an exciting and important development — it suggests an opportunity to improve care and outcomes for patients with metastatic RCC.”

“The positive top-line results from METEOR represent strong progress for the kidney cancer community and for Exelixis, bringing us one step closer to our shared goal of delivering a new and meaningfully differentiated therapeutic option for the many metastatic RCC patients in need,” said Michael M. Morrissey, Ph.D., the company’s president and chief executive officer. “With these data now in hand, Exelixis’ highest corporate priority becomes the submission of U.S. and EU regulatory filings, which we intend to complete in early 2016.”

Dr. Morrissey continued, “Delivering these top-line results for METEOR is one of multiple clinical development and regulatory milestones that we have planned for this year. These milestones collectively have the potential to significantly enhance the opportunities before us and bring value to the multiple stakeholders we serve. We look forward to sharing the detailed results of METEOR with the oncology community at an upcoming medical conference, and we thank all of the patients, families, investigators, and clinical staff who made the trial possible.”

Conference Call and Webcast

Exelixis’ management will host a conference call to discuss the METEOR results beginning at 8:30 a.m. EDT/ 5:30 a.m. PDT today, July 20, 2015. To join the call, participants may dial 877-358-0169 (domestic) or 706-679-2029 (international) and provide the conference call passcode 90168151 to join by phone. To listen to a live webcast of the conference call, visit the Event Calendar page under Investors & Media at www.exelixis.com.

An archived replay of the webcast will be available on the Event Calendar page under Investors & Media at www.exelixis.com for at least thirty days. An audio-only phone replay will be available until 11:59 p.m. EDT on July 22, 2015. Access numbers for the phone replay are: 855-859-2056 (domestic) and 404-537-3406 (international); the passcode is 90168151.

About the METEOR Phase 3 Pivotal Trial

METEOR is an open-label, event-driven trial with the primary endpoint of progression-free survival (PFS). The target enrollment for METEOR was 650 patients, and 658 patients were ultimately randomized. The trial was conducted at approximately 200 sites in 26 countries, and enrollment was weighted toward Western Europe, North America, and Australia. Patients were randomized 1:1 to receive 60 mg of cabozantinib daily or 10 mg of everolimus daily, and were stratified based on the number of prior VEGF receptor TKI therapies received, and on commonly applied RCC risk criteria developed by Motzer et al. No cross-over was allowed between the study arms.

The trial protocol specified that the primary analysis of PFS would be conducted among the first 375 patients randomized. This design was employed to ensure sufficient follow up and a PFS profile that would not be primarily weighted toward early events. Such disproportionate weighting of events was a potential risk if the entire study population required for the secondary endpoint analysis of OS had also served as the population for the primary analysis of PFS. The analysis of PFS was event-driven, and was designed to observe 259 events, providing 90% power to detect a HR of 0.67 (assuming a median PFS of 5 months for the everolimus arm and 7.5 months for the cabozantinib arm). Enrollment of the first 375 patients was completed in June 2014 and the median follow-up for these patients was 13.4 months at the time of the data cut off for the primary analysis for PFS.

Secondary endpoints for METEOR include OS and objective response rate. The secondary endpoint of OS assumes a median of 15 months for the everolimus arm and 20 months for the cabozantinib arm. The study was designed to observe 408 deaths in the entire intent-to-treat population of 650 planned patients, providing 80% power to detect a HR of 0.75. An interim analysis of OS at the 2-sided 0.0019 level per the Lan-DeMets O’Brien-Fleming alpha-spending function was planned at the time of the primary analysis for PFS, if the trial met the primary PFS endpoint.

About Metastatic Renal Cell Carcinoma

The American Cancer Society’s 2015 statistics cite kidney cancer as among the top ten most commonly diagnosed forms of cancer among both men and women in the United States.¹ Clear cell renal cell carcinoma is the most common type of kidney cancer in adults.² If detected in its early stages, the five-year survival rate for RCC is high; however, the five-year survival rate for patients with advanced or late-stage metastatic RCC is under 10 percent, with no identified cure for the disease.³

Treatments for metastatic RCC had historically been limited to cytokine therapy (e.g., interleukin-2 and interferon) until the introduction of targeted therapies into the RCC setting a decade ago. In the second and later-line setting, which encompasses approximately 17,000 drug-eligible patients in the U.S. and 37,000 globally,⁴ two therapies have been approved for the treatment of patients who have received prior VEGF receptor TKIs. However, despite the availability of several therapeutic options, currently approved agents have shown little differentiation in terms of efficacy and have demonstrated only modest PFS benefit in patients refractory to sunitinib, a commonly-used first-line therapy.

The majority of clear cell RCC tumors exhibit down-regulation of von Hippel-Lindau (VHL) protein function, either due to gene inactivation or epigenetic silencing, resulting in a stabilization of the hypoxia-inducible transcription factors (HIFs) and consequent up-regulation of VEGF, MET, and AXL.⁵ The up-regulation of VEGF may contribute to the angiogenic nature of clear cell RCC, and expression of MET or AXL may be associated with tumor cell viability, a more invasive tumor phenotype, and reduced overall survival. ⁶ Up-regulation of MET and AXL in clear cell RCC has also been shown to occur in response to treatment with VEGF receptor TKIs in preclinical models, indicating a potential role for MET and AXL in the development of resistance to these therapies.⁷

About Cabozantinib

Cabozantinib inhibits the activity of tyrosine kinases including MET, VEGF receptors, AXL, and RET. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, and maintenance of the tumor microenvironment.

COMETRIQ^® (cabozantinib) is currently approved by the U.S. Food and Drug Administration for the treatment of progressive, metastatic medullary thyroid cancer (MTC).

The European Commission granted COMETRIQ conditional approval for the treatment of adult patients with progressive, unresectable locally advanced or metastatic MTC. Similar to another drug approved in this setting, the approved indication states that for patients in whom Rearranged during Transfection (RET) mutation status is not known or is negative, a possible lower benefit should be taken into account before individual treatment decisions.

Important Safety Information, including Boxed WARNINGS

WARNING: PERFORATIONS AND FISTULAS, and HEMORRHAGE

• Serious and sometimes fatal gastrointestinal perforations and fistulas occur in COMETRIQ-treated patients.
• Severe and sometimes fatal hemorrhage occurs in COMETRIQ-treated patients.
• COMETRIQ treatment results in an increase in thrombotic events, such as heart attacks.
• Wound complications have been reported with COMETRIQ.
• COMETRIQ treatment results in an increase in hypertension.
• Osteonecrosis of the jaw has been observed in COMETRIQ-treated patients.
• Palmar-Plantar Erythrodysesthesia Syndrome (PPES) occurs in patients treated with COMETRIQ.
• The kidneys can be adversely affected by COMETRIQ. Proteinuria and nephrotic syndrome have been reported in patients receiving COMETRIQ.
• Reversible Posterior Leukoencephalopathy Syndrome has been observed with COMETRIQ.
• Avoid administration of COMETRIQ with agents that are strong CYP3A4 inducers or inhibitors.
• COMETRIQ is not recommended for use in patients with moderate or severe hepatic impairment.
• COMETRIQ can cause fetal harm when administered to a pregnant woman.

Adverse Reactions – The most commonly reported adverse drug reactions (≥25%) are diarrhea, stomatitis, palmar-plantar erythrodysesthesia syndrome (PPES), decreased weight, decreased appetite, nausea, fatigue, oral pain, hair color changes, dysgeusia, hypertension, abdominal pain, and constipation. The most common laboratory abnormalities (≥25%) are increased AST, increased ALT, lymphopenia, increased alkaline phosphatase, hypocalcemia, neutropenia, thrombocytopenia, hypophosphatemia, and hyperbilirubinemia.

Please see full U.S. prescribing information, including Boxed WARNINGS, at www.COMETRIQ.com/downloads/Cometriq_Full_Prescribing_Information.pdf

Please refer to the full European Summary of Product Characteristics for full European Union prescribing information, including contraindication, special warnings and precautions for use at www.sobi.com once posted.

About Exelixis

Exelixis, Inc. is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its development and commercialization efforts primarily on COMETRIQ^® (cabozantinib), its wholly-owned inhibitor of multiple receptor tyrosine kinases. Another Exelixis-discovered compound, cobimetinib, a selective inhibitor of MEK, is being evaluated by Roche and Genentech (a member of the Roche Group) in a broad development program under a collaboration with Exelixis. For more information, please visit the company’s web site at www.exelixis.com.

Forward-Looking Statement Disclaimer

The statements in this press release that Exelixis plans to complete U.S. and EU regulatory filings in early 2016, that the trial will continue to the final analysis of OS which is anticipated in early 2016, that detailed results of the trial will be submitted for presentation at an upcoming medical conference, that the results of the trial suggest an opportunity to improve care and outcomes for patients with metastatic RCC, regarding the potential that delivering upon top-line results for METEOR and other planned clinical development and regulatory milestones for this year will significantly enhance the opportunities before Exelixis and bring value to the multiple stakeholders Exelixis serves, are forward-looking statements that are subject to risk and uncertainty. These forward-looking statements are based upon Exelixis’ current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation: the clinical, therapeutic and commercial value of cabozantinib; the availability of data at the expected times; risks related to the potential failure of cabozantinib to demonstrate safety and efficacy in clinical study; Exelixis’ ability to conduct clinical trials of cabozantinib sufficient to achieve a positive completion; risks and uncertainties related to regulatory review and approval processes and Exelixis’ compliance with applicable legal and regulatory requirements; the general sufficiency of Exelixis’ capital and other resources; the uncertain timing and level of expenses associated with the development of cabozantinib; market competition; changes in economic and business conditions; and other factors discussed under the caption “Risk Factors” in Exelixis’ quarterly report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on April 30, 2015, and in Exelixis’ other filings with the SEC. The forward-looking statements made in this press release speak only as of the date of this press release. Exelixis expressly disclaims any duty, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Exelixis’ expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Exelixis, the Exelixis logo, and COMETRIQ are registered U.S. trademarks.

¹ Cancer Facts & Figures 2015. American Cancer Society. Available at

http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf

² Jonasch et al., BMJ (2014) vol. 349, g4797.

³ http://www.cancer.org/cancer/kidneycancer/detailedguide/kidney-cancer-adult-survival-rates

⁴ ACS Cancer Facts and Figures 2015; Heng et al., Ann Oncol (2012) vol. 23 no. 6; internal data on file; Motzer et al., N Engl J Med (2007) vol. 356 no. 2; NCIN (UK) report, April 2014, Available at http://www.ncin.org.uk/view?rid=2676.

⁵ Harschman and Choueiri, Cancer J. 2013 v19 316-323; Rankin et al., PNAS, 2014.

⁶ Bommy-Reddi et al., PNAS, 2008; Gibney et al., Ann. Oncol. 2013 v24 343-349; Koochekpour et al., Mol. Cell. Biol. 1999, v19 5902-5912; Rankin et al., PNAS, 2014.

⁷ Ciamporcero et al., MolCancerTher, 2014; Rankin et al., PNAS, 2014.

(XGTI) Implements Reverse Stock Split, Effective Friday, July 17, 2015

SARASOTA, Fla., July 20, 2015  — xG Technology, Inc. (“xG” or the “Company”) (Nasdaq: XGTI, XGTIW), a developer of patented wireless communications and spectrum sharing technologies, announced that its 1-for-10 reverse split (the “Reverse Stock Split”) of its common stock (the “Common Stock”)  became effective at  5:00 p.m. Eastern Time on Friday, July 17, 2015, and the Common Stock will open for trading on July 20, 2015 on a post-split basis.

In connection with the Reverse Stock Split, the CUSIP number for the Common Stock has been changed to 98372A 507.

Information to Stockholders

Continental Stock Transfer & Trust Company is acting as exchange agent for the Reverse Stock Split and will send instructions to stockholders of record who hold stock certificates regarding the exchange of certificates for Common Stock. Stockholders who hold their shares of Common Stock in brokerage accounts or “street name” are not required to take any action to effect the exchange of their shares following the Reverse Stock Split. Continental Stock Transfer & Trust Company may be reached for questions at (212) 509-4000.

More information on the Reverse Stock Split can be found in xG’s Form 8-K, which will be filed with the Securities and Exchange Commission on July 20, 2015. Additional information on xG’s Reverse Stock Split will be available beginning on or about July 20, 2015 in “Frequently Asked Questions” on the Company’s website at www.xgtechnology.com.

About xG Technology

xG Technology has created a broad portfolio of intellectual property that makes wireless networks more intelligent, accessible, affordable and reliable. The company has created xMax, a patented all-IP cognitive radio technology that enables robust mobile broadband communications for private, consumer and government networks. xMax can solve the crisis facing the wireless industry caused by data-hungry devices and applications that are straining network capacity. It eliminates the need to acquire scarce and expensive licensed spectrum, thus lowering the total cost of ownership for wireless broadband access. xG’s goal is to help wireless broadband networks deliver voice, video and data services to fixed and mobile users. The xMax cognitive radio system incorporates advanced optimizing technologies that include spectrum sharing, interference mitigation, multiple-input multiple-output (MIMO) and software defined radio (SDR). These and other technologies make xMax ideal for wide area, as well as rapid emergency communication deployment. xG offers solutions for numerous industries worldwide, including urban and rural wireless broadband, utilities, defense, emergency response and public safety.

Based in Sarasota, Florida, xG has 60 U.S. and over 130 international patents and pending patent applications. xG is a publicly traded company listed on the NASDAQ Capital Market where xG common stock is traded under the symbol XGTI and xG warrants are traded under the symbol XGTIW. For more information, please visit www.xgtechnology.com.

Cautionary Statement Regarding Forward Looking Statements

Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Company’s expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties.  These statements include but are not limited to statements regarding the intended terms of the offering, closing of the offering and use of any proceeds from the offering. When used herein, the words “anticipate,” “believe,” “estimate,” “upcoming,” “plan,” “target”, “intend” and “expect” and similar expressions, as they relate to xG Technology, Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company’s actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.

For More Information:

Media Relations
Daniel Carpini
xG Technology, Inc.
daniel.carpini@xgtechnology.com
(941) 953-9035

Investor and Analyst Relations
James Woodyatt
xG Technology, Inc.
james.woodyatt@xgtechnology.com
(954) 572-0395

Jody Burfening/Carolyn Capaccio
LHA
ccapaccio@lhai.com
(212) 838-3777

(REPH) Positive Top-Line Results for Phase II Clinical Trial of Dex-IN

Company Plans to Meet With FDA to Discuss Phase III Clinical Program

MALVERN, Pa., July 17, 2015  — Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of acute post operative pain, today announced positive efficacy results in the Phase II clinical trial for Dex-IN, a proprietary intranasal formulation of dexmedetomidine, for the treatment of acute pain in adult patients undergoing bunionectomy surgery. Dex-IN met the primary endpoint of the clinical trial in demonstrating significant pain relief compared with placebo over 48 hours. The Company plans to meet with the FDA to discuss the Company’s Phase III plans and determine what, if any, additional information will be required in association with the Phase III clinical program for Dex-IN.

“The positive top line results support the potential of Dex-IN, a non-opioid alternative, to treat acute post operative pain,” said Gerri Henwood, Recro Pharma’s President and Chief Executive Officer. “We look forward to discussing these Phase II results with the FDA and progressing into pivotal Phase III clinical trials.”

The Phase II trial was a randomized, multicenter, double-blind, placebo-controlled study to evaluate the efficacy and safety of Recro Pharma’s proprietary intranasal formulation of dexmedetomidine, Dex-IN, in adult patients undergoing bunionectomy surgery, initiating dosing of study medication on Post Op Day 1. Patients who met the eligibility criteria were randomized to either a 50µg dose of Dex-IN or a placebo intranasal dose given every 6 hours. Following the beginning of treatment, patients remained under observation for 48 hours at study centers. Patients were followed for 7 days after the initial dose of study medication. There was an oral opioid rescue treatment available to patients in either treatment group, if required, to provide adequate pain relief. A total of 168 patients were randomized and received study medication in the clinical trial, 84 patients in each treatment group. Seven patients discontinued the study early, six for lack of efficacy (three in each treatment group) and one for a serious adverse event of hypotension.

The primary efficacy endpoint of the trial was the summed pain intensity difference over 48 hours, SPID48, starting on Post Op Day 1. Additional efficacy endpoints included use of opioid rescue medication, SPIDs over various time intervals, as well as other standard efficacy analyses. The most common adverse events observed in the study were blood pressure decrease / hypotension, nausea (similar incidences to placebo), nasal discomfort and headache. An adverse event of bradycardia was reported in 3 subjects in the Dex-IN treatment group.

Bunionectomy surgery generally involves an incision in the top or side of the big toe joint and the removal or realignment of soft tissue and bone. This is done to relieve pain and restore normal alignment to the joint. Bunionectomy surgery typically results in intense post operative pain. In the past, drugs that have demonstrated analgesic effectiveness following bunionectomy surgery have frequently translated that analgesic success into other post operative procedures that result in moderate to severe, acute pain.

About Recro Pharma, Inc.

Recro Pharma is a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of acute post operative pain. Recro Pharma is currently developing IV/IM meloxicam, a proprietary, Phase III-ready, long-acting preferential COX-2 inhibitor, and Dex-IN, a proprietary intranasal formulation of dexmedetomidine currently being tested in Phase II, for the treatment of acute post operative pain. As Recro Pharma’s product candidates are not in the opioid class of drugs, the Company believes its candidates would avoid many of the side effects associated with commonly prescribed opioid therapeutics, such as addiction, constipation and respiratory distress, while maintaining analgesic effect.

Recro Pharma also owns and operates an 87,000 square foot, DEA-licensed facility that manufactures five commercial products and receives royalties associated with the sales of these products.

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties. Such forward-looking statements reflect Recro Pharma’s expectations about its future performance and opportunities that involve substantial risks and uncertainties. When used herein, the words “anticipate,” “believe,” “estimate,” “upcoming,” “plan,” “target”, “intend” and “expect” and similar expressions, as they relate to Recro Pharma or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information available to Recro Pharma as of the date of this press release and are subject to a number of risks, uncertainties, and other factors that could cause Recro Pharma’s performance to differ materially from those expressed in, or implied by, these forward-looking statements. Recro Pharma assumes no obligation to update any such forward-looking statements. Factors that could cause Recro Pharma’s actual performance to materially differ from those expressed in the forward-looking statements set forth in this press release include, without limitation: results and timing of the clinical trials of IV/IM meloxicam and Dex-IN; the ability to obtain and maintain regulatory approval of IV/IM meloxicam and Dex-IN, and the labeling under any such approval; regulatory developments in the United States and foreign countries; the Company’s ability to raise future financing for continued development; the performance of third-party suppliers and manufacturers; the Company’s ability to obtain, maintain and successfully enforce adequate patent and other intellectual property protection; the successful commercialization of IV/IM meloxicam and Dex-IN; In addition, the forward-looking statements in this press release should be considered together with the risks and uncertainties that may affect Recro Pharma’s business and future results included in Recro Pharma’s filings with the Securities and Exchange Commission at www.sec.gov. Recro Pharma assumes no obligation to update any such forward looking statements.

CONTACT: Recro Pharma, Inc.
         Charles T. Garner
         Chief Financial Officer
         (484) 395-2425

         Media and Investors:
         Argot Partners
         Susan Kim
         (212) 600-1902
         susan@argotpartners.com

(VRML) Announces Closing of $18.8 Million Public Offering of Common Stock

AUSTIN, Texas, July 17, 2015  — Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, today announced the closing of an underwritten public offering of 9,602,500 shares of its common stock, including 1,252,500 shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares at a price to the public of $1.96 per share.

Canaccord Genuity acted as sole book-running manager and Roth Capital Partners acted as lead manager for the offering.

The net proceeds from the sale of the shares of common stock, after deducting the underwriting discount and the other offering expenses, are expected to be approximately $17.5 million.  Vermillion intends to use the net proceeds from the offering to fund domestic and international commercialization, bioinformatics platform enhancements, portfolio expansion and general corporate purposes.

The offering was made pursuant to a shelf registration statement (File No. 333-198734) previously filed with and declared effective by the U.S. Securities and Exchange Commission (SEC). This offering was made only by means of a prospectus supplement and accompanying base prospectus. A final prospectus supplement and the accompanying prospectus describing the terms of the offering were filed with the SEC on June 14, 2015 and are available on the SEC’s website at www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus may also be obtained by contacting the Syndicate Department of Canaccord Genuity Inc., Attention: Syndicate Department, 99 High Street, 12th Floor, Boston, Massachusetts 02110, or by telephone/email at (800) 225-6201/prospectus@canaccordgenuity.com.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

About Vermillion, Inc. – Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. Vermillion, along with its prestigious scientific collaborators, have diagnostic programs in gynecologic disease. Vermillion’s lead diagnostic, OVA1^®, is a blood test for pre-surgical assessment of ovarian tumors for malignancy, using an innovative algorithmic approach. As the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, OVA1 represents a new class of software-based diagnostics.

Vermillion and VRML are trademarks of Vermillion, Inc.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended.  All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding Vermillion’s anticipated use of proceeds from the public offering.  In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions.  These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including risks and uncertainties inherent in Vermillion’s business, including those described in the section entitled “Risk Factors” in Vermillion’s Annual Report on Form 10-K for the year ended December 31, 2014 and in Vermillion’s other periodic filings with the SEC.  The events and circumstances reflected in Vermillion’s forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements.  Except as required by applicable law, Vermillion does not plan to publicly update or revise any forward-looking statements contained in this press release, whether as a result of any new information, future events, changed circumstances or otherwise.

Investor Relations Contact:
Michael Wood
LifeSci Advisors LLC
Tel 1-646-597-6983
mwood@lifesciadvisors.com

(FBIO) Subsidiary, Altamira Bio, Acquires ManNAc NIH License and CRADAs

ManNAc to be Studied as Potential Treatment of Hereditary Inclusion Body Myopathy (HIBM) and Various Nephropathies Associated With Hyposialylation

NEW YORK, July 17, 2015  — Fortress Biotech, Inc. (NASDAQ:FBIO) announced that its subsidiary, Altamira Bio, acquired from New Zealand Pharmaceuticals Ltd (NZP), a license from the National Institutes of Health (NIH) and Cooperative Research and Development Agreements (CRADAs) for the development of oral N-acetyl-D-mannosamine (ManNAc), a key compound in the sialic biosynthetic pathway, for the treatment of hyposialylation disorders. Hyposialylation disorders are a group of pathologies associated with abnormal sialylation of tissues, characteristic of Hereditary Inclusion Body Myopathy (HIBM), also known as GNE myopathy – a rare genetic disorder which causes progressive muscle-wasting and weakness.

New Zealand Pharmaceuticals Ltd (NZP) manufactures ManNAc (DEX-M74) and will remain the exclusive global supplier of ManNAc to Altamira Bio.

“HIBM, a severe debilitating muscle-wasting disease with unmet medical need, has a clearly established genetic link,” said Dr. Lindsay A. Rosenwald, Chairman, President and CEO of Fortress Biotech. “Thanks to the work conducted by NIH scientists to date, we have very compelling data on how ManNAc administration could supplement the genetic insufficiency to help these patients to normalize protein sialylation and retain their muscle strength. We are pleased to be working with NIH scientists in the NHGRI division who are leaders in this field in bringing this potential therapy to patients. We are also encouraged by recent discoveries on the possible involvement of hyposialylation in kidney diseases and testing ManNAc in patients with nephropathies for improving their kidney function.”

About GNE Myopathy

HIBM (GNE Myopathy) is a rare genetic disease inflicting approximately 2000 people worldwide. Disease symptoms emerge in adulthood and slowly lead to progressive muscle weakness. Most patients develop symptoms in their early 20s and eventually require a wheelchair as their arm, hand and leg muscles weaken. The disease is caused by mutations in GNE gene, which codes for a rate-limiting enzyme in the sialic acid synthesis pathway. Dysfunction in GNE in HIBM leads to impaired sialylation of certain glycoproteins and glycolipids believed to be responsible for the gradual muscle deterioration.

About ManNAc

N-acetyl-D-mannosamine (ManNAc) is an intermediate in sialic acid biosynthesis generated by functional GNE protein. Supplementation of ManNAc to the cells with dysfunctional GNE protein bypasses the need for GNE function and enables protein sialylation. ManNAc has been demonstrated in human studies to significantly increase circulating levels of sialic acid and is shown to treat disease in mouse models of both HIBM and kidney diseases. The FDA has provided orphan designation for ManNAc in HIBM. ManNAc is currently under investigation in an open label Phase I/II study for the treatment of the rare muscle-wasting disease Hereditary Inclusion Body Myopathy (HIBM), also known as GNE Myopathy. A protocol for a Phase I study to further investigate ManNAc safety and tolerability in various kidney diseases (nephropathies) associated with hyposialylation is under IRB review.

About Altamira Bio

Altamira Bio is a development stage company focused on the clinical development and commercialization of N-acetyl-D-mannosamine (ManNAc) and other therapies for orphan/rare disorders.

About Fortress Biotech

Fortress Biotech, Inc. (“Fortress” or “the Company”) is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress plans to develop and commercialize products that it acquires both directly as well as indirectly by establishing subsidiary companies, also known as Fortress Companies. The Company intends to leverage its biopharmaceutical business expertise and drug development capabilities to help the Fortress Companies achieve their goals. Additionally, the Company intends to provide funding and management services to each of the Fortress Companies and from time to time the Company and the Fortress Companies will seek licensing, partnerships, joint ventures, and/or public and private financings to accelerate and provide additional funding to support their research and development programs. For more information, visit www.fortressbiotech.com.

Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

CONTACT: Lucy Lu, MD, Executive Vice President &
         Chief Financial Officer
         Fortress Biotech, Inc.
         781-652-4525; ir@fortressbiotech.com

(TOR) Built New Organizational Structure to Offer Diversified Services

CHANGSHU, China, July 17, 2015  — Sutor Technology Group Limited (the “Company” or “Sutor”) (Nasdaq: TOR), one of the leading China-based manufacturers and service providers for fine finished steel products used by a variety of downstream applications, today announced that Company adjusted its organizational structure recently to provide customers with diversified services and consolidate the Company’s business transformation achievements.

To provide diversified services and realize “asset-light” operation, the Company built a new organizational structure. This new structure can help us integrate our internal and external resources in order to achieve our goal of becoming “one of the best service platforms in the industrial ecological chain”. The principle of such new organizational structure is “simple and effective flat management”. Under the new structure, there are three major parallel divisions compromising business, technical and operational divisions. Business division is composed of supply chain development department, logistic department, international e-business department, product innovation department and IE (integrate, industrial and internet education) department. Technical division is composed of factory services department and IT department. Operational division is composed of financing services department, public relations services department, customer services department and investment development services department.

Ms. Lifang Chen, Chairwoman and CEO of Sutor commented, “We are glad to see that, through all of our employees’ efforts, the Company completed the business transformation from a fine finished steel manufacturer into a fine finished steel supply chain service provider. To better fulfill our responsibilities of providing comprehensive one-stop services in processing, logistics, e-commerce and R&D to our end customers, we adjusted the organizational structure.”

About Sutor Technology Group Ltd

Sutor is one of the leading China-based manufacturers and service providers for high-end fine finished steel products and welded steel pipes used by a variety of downstream applications. The Company utilizes a variety of in-house developed processes and technologies to convert steel manufactured by third parties into fine finished steel products, including hot-dip galvanized steel, pre-painted galvanized steel, acid-pickled steel, cold-rolled steel and welded steel pipe products. The Company also provides fee-based steel processing services to customers, including industrial peers. To learn more about the Company, please visit http://www.sutorcn.com/en/index.php.

Forward-Looking Statements

This press release includes certain statements that are not descriptions of historical facts, but are “forward-looking statements” in nature within the meaning of the Private Securities Litigation Reform Act of 1995.  Such statements include, among others, those concerning our expected financial performance, liquidity and strategic and operational plans, our future operating results, our expectations regarding the market for our products, our expectations regarding the steel market, as well as all assumptions, expectations, predictions, intentions or beliefs about future events.  You are cautioned that any such forward-looking statements are not guarantees of future performance and that a number of risks and uncertainties could cause our actual results to differ materially from those anticipated, expressed or implied in the forward-looking statements.  These risks and uncertainties include, but not limited to, the factors mentioned in the “Risk Factors” section of our Annual Report on Form 10-K for the year ended June 30, 2014, and other risks mentioned in our other reports filed with the Securities Exchange Commission (“SEC”).  Copies of filings made with the SEC are available through the SEC’s electronic data gathering analysis retrieval system (EDGAR) at http://www.sec.gov. The words “believe,” “expect,” “anticipate,” “project,” “targets,” “optimistic,” “intend,” “aim,” “will” or similar expressions are intended to identify forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements.  The Company assumes no obligation and does not intend to update any forward-looking statements, except as required by law.

For more information, please contact:
Investor Relations
Sutor Technology Group Limited
Tel: +86-512-5268-0988
Email: investor_relations@sutorcn.com

(TNXP) Closes $20.1 Million Public Offering of Common Stock

NEW YORK, July 17, 2015  — Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (“Tonix”) today announced the closing of its previously announced underwritten public offering of 2,325,000 shares of its common stock, as well as the sale of 348,750 additional shares pursuant to the full exercise of the over-allotment option granted to the underwriters. The shares were sold in the offering at a public offering price of $7.50 per share, resulting in gross proceeds to Tonix of approximately $20.1 million, before deducting the underwriting discount and other offering expenses payable by Tonix.

Roth Capital Partners and Oppenheimer & Co. acted as joint book-running managers for the offering. Janney Montgomery Scott acted as co-manager in this offering.

The shares described above were offered by Tonix pursuant to a registration statement previously filed with, and subsequently declared effective by, the Securities and Exchange Commission (“SEC”). A prospectus supplement relating to the offering has also been filed with the SEC and is available, along with the accompanying base prospectus, on the SEC’s website at http://www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Tonix Pharmaceuticals Holding Corp.

Tonix is dedicated to the development of next-generation medicines for common yet challenging disorders of the central nervous system, characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and significant economic burden. Tonix’s Tonmya^TM is currently being evaluated in the Phase 3 AFFIRM study in fibromyalgia. TNX-102 SL, the same proprietary product candidate as Tonmya, is currently being evaluated in the Phase 2 AtEase study in post-traumatic stress disorder. A Phase 2 proof-of-concept study of TNX-201 in episodic tension-type headache is ongoing. This press release and further information about Tonix can be found at www.tonixpharma.com.

CONTACT: Tonix Pharmaceuticals Holding Corp.
         Leland Gershell
         Chief Financial Officer
         (212) 980-9155 x104
         leland.gershell@tonixpharma.com

         Investor Relations
         Martini Communications
         Amy Martini
         amartini@martinicommunications.com

         Public Relations
         Dian Griesel Int'l.
         Susan Forman / Laura Radocaj
         (212) 825-3210
         sforman@dgicomm.com
         lradocaj@dgicomm.com

(ICLD) New Contracts for Next-Generation WiFi/DAS Business of Over $2.3 Million

SHREWSBURY, N.J., July 17, 2015  — InterCloud Systems, Inc. (Nasdaq:ICLD), a leading provider of cloud networking orchestration and automation solutions and services, announced today that it was recently awarded over $2.3 million in next-generation WiFi and DAS networks from existing and new clients. The work on these projects is expected to be completed between Q-3 and Q-4 of 2015.

Mark Munro, CEO of InterCloud Systems stated: “The new contracts from existing customers support that InterCloud continues to deliver industry leading solutions to our demanding customers. The addition of new customers also validates our company’s broad platform of services. Our management team remains focused on continuing to build a portfolio of next-generation IT services that will keep InterCloud competitive over the next several years as the IT industry continues to build momentum in cloud and managed services. Customers are in need of companies like InterCloud that can deliver leading edge solutions in cloud today and also assist them in navigating through this disruption and confusion in the marketplace.”

About InterCloud Systems, Inc.

InterCloud Systems, Inc. is a single-source provider of end-to-end information technology (IT) and next-generation network solutions including Software Defined Networking (SDN) and Network Function Virtualization (NFV) to the service provider (carrier) and corporate enterprise markets through cloud solutions and professional services. InterCloud offers cloud and managed services, professional services, and infrastructure and applications, to assist its customers in meeting their changing technology demands. InterCloud’s cloud solutions offer enterprise and service-provider customers the opportunity to adopt an operational expense model by outsourcing to InterCloud, rather than the capital expense model that has dominated in recent decades. Additional information regarding InterCloud may be found on InterCloud’s website at www.intercloudsys.com.

Forward-looking statements:

The above news release contains forward-looking statements. The statements contained in this document that are not statements of historical fact, including but not limited to, statements identified by the use of terms such as “anticipate,” “appear,” “believe,” “could,” “estimate,” “expect,” “hope,” “indicate,” “intend,” “likely,” “may,” “might,” “plan,” “potential,” “project,” “seek,” “should,” “will,” “would,” and other variations or negative expressions of these terms, including statements related to expected market trends and the Company’s performance, are all “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and involve a number of risks and uncertainties. These statements are based on assumptions that management believes are reasonable based on currently available information, and include statements regarding the intent, belief or current expectations of the Company and its management. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performances, and are subject to a wide range of external factors, uncertainties, business risks, and other risks identified in filings made by the company with the Securities and Exchange Commission. Actual results may differ materially from those indicated by such forward-looking statements. The Company expressly disclaims any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based except as required by applicable law and regulations.

CONTACT: Investor Relations
         InterCloud Systems, Inc.
         Telephone 561-988-1988
         Website www.intercloudsys.com

(GLUU) Launches Mission: Impossible Mobile Game Ahead of the Worldwide Theatrical Release

Glu Mobile Inc. (NASDAQ: GLUU), a leading global developer and publisher of free-to-play games for smartphone and tablet devices, today announced the availability of the Mission: Impossible – Rogue Nation mobile game on the App Store and Google Play. Under license from Paramount Pictures and in creative collaboration with Skydance, Glu has developed the official mobile game in conjunction with the highly anticipated feature film Mission: Impossible – Rogue Nation, which is scheduled for U.S. theatrical release on July 31, 2015.

“We are excited to deliver the first ever free-to-play Mission: Impossible mobile game as part of Glu’s ongoing partnerships with Paramount Pictures and Skydance,” said Niccolo de Masi, Glu Chairman and CEO. “Mission: Impossible – Rogue Nation’s intense action gameplay introduces players to exotic locations from the upcoming film while incorporating engaging social components such as PvP, co-op agencies, and in-game chat.”

“We are thrilled to provide a new way for our global audience to interact with the Mission Impossible franchise,” said LeeAnne Stables, President of Consumer Products for Paramount Pictures. “This action-packed mobile game from Glu brings the excitement of the new movie right into the hands of fans.”

“The Mission: Impossible – Rogue Nation film takes the action, adventure and stakes to a new level and the team at Glu did a fantastic job of incorporating these elements in new and innovative ways through the mobile game,” added Jesse Sisgold, Chief Operating Officer of Skydance.

About the Mission: Impossible – Rogue Nation Mobile Game

Your mission, should you choose to accept it… Join the Impossible Mission Force (IMF) to infiltrate secure locations and eliminate high-profile targets, perform lethal strikes and confront the Syndicate. Travel across the globe to exotic locations like Morocco, London, and Vienna to collect intelligence and take on enemy threats. Choose among story, heavy gun, gauss rifle, repeatable, and stealth missions to accomplish your goal of eliminating the Syndicate once and for all. Join other players to build an agency, complete missions and earn team rewards. Communicate with fellow IMF agents through chat to share tips and tricks. This message will self-destruct…

Features of the Mission: Impossible – Rogue Nation Mobile Game

• Track the Syndicate Across the Globe – Travel to exotic locations as you take out enemy agents, destroy rogue bases, and eliminate the boss in each region!
• Complete Impossible Missions – Complete each mission’s objective as you stop the Syndicate and assist the IMF. Stake out targets from long range, take them down with well-placed shots, assault enemy bases head-on, or infiltrate enemy lines without compromising your identity.
• Equip Advanced Weaponry and Gear – Load up on weapons such as sniper rifles, assault rifles, heavy guns and gauss rifles, and then upgrade them. Don’t forget to grab the latest gear: rocket launchers, throwing knives, med kits, armor and more!
• Destroy Enemy Bases and Build Your Defenses – Build your IMF headquarters defenses to protect your resources and assault and steal other players’ headquarters! Fortify your defenses with upgrades such as turrets to repel even the most stubborn attackers.
• Join and Form Agencies – Create an IMF agency with other players and work together to win agency events.

Paramount Pictures and Skydance present a Tom Cruise / Bad Robot Production, “MISSION: IMPOSSIBLE – ROGUE NATION.” With the IMF disbanded and Ethan (Tom Cruise) out in the cold, the team now faces off against a network of highly skilled special agents, the Syndicate. These highly trained operatives are hellbent on creating a new world order through an escalating series of terrorist attacks. Ethan gathers his team and joins forces with disavowed British agent Ilsa Faust (Rebecca Ferguson), who may or may not be a member of this rogue nation, as the group faces its most impossible mission yet. Starring Tom Cruise, Jeremy Renner, Simon Pegg, Rebecca Ferguson, Ving Rhames, Sean Harris and Alec Baldwin.

The film is directed by Christopher McQuarrie, with a screenplay by Christopher McQuarrie and story by Christopher McQuarrie and Drew Pearce. Based on the television series created by Bruce Geller. Produced by Tom Cruise, J.J. Abrams, Bryan Burk, David Ellison, Dana Goldberg and Don Granger. Jake Myers is an executive producer.

Paramount Pictures will distribute “MISSION: IMPOSSIBLE – ROGUE NATION” on July 31, 2015.

The Mission: Impossible – Rogue Nation game is available for free from the App Store on iPhone, iPad, or iPod touch at http://bit.ly/1fH0SpT, on Google Play at http://bit.ly/1K6uYNd, and the Amazon Appstore at http://amzn.to/1OdGo36.

For updates and information about the game, visit: http://www.glu.com/missionimpossible5game

About Glu Mobile

Glu Mobile (NASDAQ:GLUU) is a leading global developer and publisher of free-to-play games for smartphone and tablet devices. Glu is focused on creating compelling original IP games such as CONTRACT KILLER, COOKING DASH, DEER HUNTER, DINER DASH, DINO HUNTER: DEADLY SHORES, ETERNITY WARRIORS, FRONTLINE COMMANDO, RACING RIVALS, and TAP SPORTS BASEBALL, and branded IP games including KIM KARDASHIAN: HOLLYWOOD, ROBOCOP: THE OFFICIAL GAME, and TERMINATOR GENYSIS: REVOLUTION on the App Store, Google Play, Amazon Appstore, Facebook, Mac App Store, and Windows Phone. Glu’s unique technology platform enables its titles to be accessible to a broad audience of consumers globally. Founded in 2001, Glu is headquartered in San Francisco with major U.S. offices outside Seattle and in Long Beach, and international locations in Canada, China, India, Japan, Korea, and Russia. Consumers can find high-quality entertainment wherever they see the ‘g’ character logo or at www.glu.com. For live updates, please follow Glu via Twitter at www.twitter.com/glumobile or become a Glu fan at www.facebook.com/glumobile.

CONTRACT KILLER, COOKING DASH, DEER HUNTER, DINER DASH, DINO HUNTER: DEADLY SHORES, ETERNITY WARRIORS, FRONTLINE COMMANDO, RACING RIVALS, TAP SPORTS BASEBALL, GLU, GLU MOBILE and the ‘g’ character logo are trademarks of Glu Mobile Inc. or its subsidiaries.

About Paramount Pictures Corporation

Paramount Pictures Corporation (PPC), a global producer and distributor of filmed entertainment, is a unit of Viacom (NASDAQ: VIAB, VIA), a leading content company with prominent and respected film, television and digital entertainment brands. Paramount controls a collection of some of the most powerful brands in filmed entertainment, including Paramount Pictures, Paramount Animation, Paramount Television, Paramount Vantage, Paramount Classics, Insurge Pictures, MTV Films, and Nickelodeon Movies. PPC operations also include Paramount Home Media Distribution, Paramount Pictures International, Paramount Licensing Inc., and Paramount Studio Group.

About Skydance

Skydance is a diversified media company founded by David Ellison in 2010 to create elevated, event-level entertainment for global audiences. The Company brings to life stories of immersive worlds across platforms, including feature film, television, gaming and digital. Among Skydance’s blockbuster and award-winning feature film successes are True Grit, Star Trek Into Darkness, Mission: Impossible – Ghost Protocol, GI JOE – Retaliation, Jack Reacher, World War Z and Terminator Genisys. Skydance’s upcoming film slate features Mission: Impossible – Rogue Nation in 2015 and Geostorm, Star Trek 3 and Jack Reacher 2 in 2016. Skydance Television’s original scripted series include the critically acclaimed Manhattan on WGN and Grace and Frankie on Netflix.

(ALNY) to Reschedule First RNAi Roundtable Webcast

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that due to an unforeseen scheduling issue with its guest speaker, the first program in the company’s series of RNAi Roundtable webcasts has been rescheduled. “ALN-CC5 for the Treatment of Complement-Mediated Diseases,” which was originally scheduled for Friday, July 17, 8:00 – 9:00 a.m. ET will now take place Thursday, July 23, 9:00 – 10:00 a.m. ET. Revised details of the program are listed below. There are no additional changes at this time to any of the other Roundtable webcasts which were previously announced.

ALN-CC5 for the treatment of Complement-Mediated Diseases
Thursday, July 23, 9:00 – 10:00 a.m. ET

• Pushkal Garg, M.D., Senior Vice President, Clinical Development
• Moderator: John Maraganore, Ph.D., Chief Executive Officer
• Guest Speaker: Regis Peffault de Latour, M.D., Ph.D., Professor, Hematology and Transplantation, Saint-Louis Hospital, Paris

About RNAi
RNAi (RNA interference) is a revolution in biology, representing a breakthrough in understanding how genes are turned on and off in cells, and a completely new approach to drug discovery and development. Its discovery has been heralded as “a major scientific breakthrough that happens once every decade or so,” and represents one of the most promising and rapidly advancing frontiers in biology and drug discovery today which was awarded the 2006 Nobel Prize for Physiology or Medicine. RNAi is a natural process of gene silencing that occurs in organisms ranging from plants to mammals. By harnessing the natural biological process of RNAi occurring in our cells, the creation of a major new class of medicines, known as RNAi therapeutics, is on the horizon. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam’s RNAi therapeutic platform, target the cause of diseases by potently silencing specific mRNAs, thereby preventing disease-causing proteins from being made. RNAi therapeutics have the potential to treat disease and help patients in a fundamentally new way.

About Alnylam Pharmaceuticals
Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines. Alnylam’s pipeline of investigational RNAi therapeutics is focused in 3 Strategic Therapeutic Areas (STArs): Genetic Medicines, with a broad pipeline of RNAi therapeutics for the treatment of rare diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases; and Hepatic Infectious Disease, with a pipeline of RNAi therapeutics that address the major global health challenges of hepatic infectious diseases. In early 2015, Alnylam launched its “Alnylam 2020” guidance for the advancement and commercialization of RNAi therapeutics as a whole new class of innovative medicines. Specifically, by the end of 2020, Alnylam expects to achieve a company profile with 3 marketed products, 10 RNAi therapeutic clinical programs – including 4 in late stages of development – across its 3 STArs. The company’s demonstrated commitment to RNAi therapeutics has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, Biogen, Roche, Takeda, Kyowa Hakko Kirin, Cubist, GlaxoSmithKline, Ascletis, Monsanto, The Medicines Company, and Genzyme, a Sanofi company. In addition, Alnylam holds an equity position in Regulus Therapeutics Inc., a company focused on discovery, development, and commercialization of microRNA therapeutics. Alnylam scientists and collaborators have published their research on RNAi therapeutics in over 200 peer-reviewed papers, including many in the world’s top scientific journals such as Nature, Nature Medicine, Nature Biotechnology, Cell, New England Journal of Medicine, and The Lancet. Founded in 2002, Alnylam maintains headquarters in Cambridge, Massachusetts. For more information about Alnylam’s pipeline of investigational RNAi therapeutics, please visit www.alnylam.com.

Alnylam Forward Looking Statements
Various statements in this release concerning Alnylam’s future expectations, plans and prospects, including without limitation, Alnylam’s views with respect to the potential for RNAi therapeutics, expectations regarding its STAr pipeline growth strategy, and its plans regarding commercialization of RNAi therapeutics, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, Alnylam’s ability to discover and develop novel drug candidates and delivery approaches, successfully demonstrate the efficacy and safety of its drug candidates, the pre-clinical and clinical results for its product candidates, which may not be replicated or continue to occur in other subjects or in additional studies or otherwise support further development of product candidates, actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials, obtaining, maintaining and protecting intellectual property, Alnylam’s ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties, obtaining regulatory approval for products, competition from others using technology similar to Alnylam’s and others developing products for similar uses, Alnylam’s ability to manage operating expenses, Alnylam’s ability to obtain additional funding to support its business activities and establish and maintain strategic business alliances and new business initiatives, Alnylam’s dependence on third parties for development, manufacture, marketing, sales and distribution of products, the outcome of litigation, and unexpected expenditures, as well as those risks more fully discussed in the “Risk Factors” filed with Alnylam’s most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) and in other filings that Alnylam makes with the SEC. In addition, any forward-looking statements represent Alnylam’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Alnylam explicitly disclaims any obligation to update any forward-looking statements.

Alnylam Pharmaceuticals, Inc.
Michael Mason, 617-551-8327
Vice President, Finance and Treasurer
or
Spectrum
Liz Bryan (Media), 202-955-6222 x2526

(CETX) Announces New Orders Totaling Over $4.2M

FARMINGDALE, N.Y., July 16, 2014  — Cemtrex Inc., (CETX) today announced that the company has received new orders in excess of $4,200,000 across its two business groups: Environmental Products & Systems and Electronics Manufacturing Services.

The company received approximately $2.5M in new environmental products sales with deliveries expected over the next twelve months for new projects located in Southeast Asia. The company also received approximately $1.7M in new electronics products orders for a diverse set of existing European customers in medical, industrial, and automation industries with deliveries expected over the next twelve months.

Cemtrex’s CEO, Saagar Govil, commented, “We are continuing to see demand in both of our important markets where there are overall economic concerns, Europe and Asia. We are confident that with our product portfolio, niche industry segments, and continued demand from our customers we can continue to grow our business despite outside market concerns.”

About Cemtrex, Inc.
Cemtrex, Inc. (NASDAQ:CETX) is a world leading diversified industrial and manufacturing company that provides a wide array of solutions to meet today’s technology challenges. Cemtrex provides electronic manufacturing services of custom engineered printed circuit board assemblies, emission monitors & instruments for industrial processes, and environmental control & air filtration systems for industries & utilities.
www.cemtrex.com

Safe Harbor Statement
This press release contains forward-looking statements. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date.

For further information, please contact:

Cemtrex Inc.
Saagar Govil
Phone: 631-756-9116
Email

(UUUU) Receives Mine Permit from State of Wyoming for Its Sheep Mountain Uranium Project

Energy Fuels Inc. – Investor Inquiries:
Curtis Moore
VP – Marketing and Corporate Development
(303) 974-2140 or Toll free: (888) 864-2125
investorinfo@energyfuels.com
www.energyfuels.com

(ISR) Cesium-131 Cancer Fighting Portfolio on Display at AAPM Convention

(AMRS) Multi-Year, Multi-Million-Dollar Agreement With Global Food Ingredients Supplier

Marks Amyris’s First Collaboration Agreement in Food Sector

EMERYVILLE, Calif., July 16, 2015  — Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced a multi-year, multi-million-dollar collaboration agreement with a global food ingredients supplier. This agreement marks Amyris’s first collaboration in the growing food ingredients sector. The partner will provide funding for the development program, which Amyris will be responsible for executing, and the agreement includes a long-term value share provision in regard to future end-market product sales by the partner. Under the terms of the agreement, the company is unable to disclose details of the collaboration.

“We’re excited with the continued momentum in executing our plan with growing our collaboration partnerships,” said John Melo, President & CEO of Amyris. “This collaboration adds to our current portfolio of collaboration partners and our growing portfolio of over 20 products under agreement with more than 10 partners. We are on track to introduce three new commercial products this year for our partners as a result of our earlier collaborations. Collaborations continue to fund our direct R&D costs and provide strong product revenue growth.”

About Amyris

Amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients and consumer products. The company is delivering its No Compromise® products in focused markets, including specialty and performance chemicals, fragrance ingredients, and cosmetic emollients. More information about the company is available at www.amyris.com.

Forward-Looking Statements

This release contains forward-looking statements, and any statements other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as growing collaboration partnerships and product offerings, introduction of three new commercial products in 2015, and funding and prospects for a new collaboration) that involve risks and uncertainties. These statements are based on management’s current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks related to manufacturing capacity at Amyris’s Brotas facility, delays or failures in development, production and commercialization of products, liquidity and ability to fund capital expenditures, Amyris’s reliance on third parties to achieve its goals, and other risks detailed in the “Risk Factors” section of Amyris’s quarterly report on Form 10-Q filed on May 5, 2015. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.

Amyris is a registered trademark of Amyris, Inc.

CONTACT: Peter DeNardo
         Director, Investor Relations and Corporate Communications
         Amyris, Inc.
         +1 (510) 740-7481
         investor@amyris.com

(NVIV) Significant Improvement of 2nd & 3rd Patients Implanted with Neuro-Spinal Scaffold

InVivo Therapeutics Holdings Corp. (NVIV) today announced a one-month post-implant update for the third study patient and a six-month post-implant update for the second study patient in the company’s ongoing pilot trial of its investigational Neuro-Spinal Scaffold in patients with complete acute spinal cord injury.

In the time between implantation and the one-month post-injury assessment of the third study patient, the patient improved from a complete AIS A spinal cord injury to an incomplete AIS B spinal cord injury. The patient has regained sacral sensation with improved bladder function. Historically, fewer than 4% of patients with a high thoracic neurologic level of injury convert from AIS A to AIS B in the first month after injury. There were no reported serious adverse events associated with the Neuro-Spinal Scaffold.

The second patient demonstrated marked improvement in sensory function with partial sensation present five dermatome levels lower on the right side compared to the three-month assessment. This translates to regaining partial sensation from the lower ribs to the hip on the right. The patient continues to make meaningful progress in activities of daily living.

The Neuro-Spinal Scaffold was implanted in both patients by Dr. Dom Coric of Carolina Neurosurgery and Spine Associates, Chief of Neurosurgery at the Carolinas Medical Center (CMC) in Charlotte, NC. The study is being led at CMC by Dr. Coric and Dr. William Bockenek, Chief Medical Officer of Carolinas Rehabilitation and Chairman of the Department of Physical Medicine and Rehabilitation at CMC.

Dr. Coric said, “I am very encouraged with the third patient’s neurologic recovery following successful implantation of the investigational Neuro-Spinal Scaffold.” Dr. Bockenek further stated, “It is exciting and promising when a patient who is classified as a complete spinal cord injury becomes classified as incomplete. This is a relatively unusual occurrence and gives much more potential for further recovery.”

Mark Perrin, InVivo’s CEO, said, “We are excited about the neurologic progress that each of our three study patients has made to date. It is particularly noteworthy that two of the patients improved rapidly within the first month post-injury from a complete to incomplete spinal cord injury. Patient number one improved from AIS A to AIS C in one month which occurs in fewer than 5% of AIS A patients with T10-T12 injury, and patient number three exhibited improvement AIS A to AIS B which historically is observed in fewer than 4% of patients with a T4 injury. To date, the Neuro-Spinal Scaffold has been successfully implanted in three consecutive patients with no serious adverse events associated with either the scaffold or the surgical procedure. We look forward to continuing to follow these patients and expect to complete enrollment of the remaining two patients in our pilot trial within the coming months.”

About the Neuro-Spinal Scaffold

Following an acute spinal cord injury, the biodegradable Neuro-Spinal Scaffold is surgically implanted at the epicenter of the wound and is designed to act as a physical substrate for nerve sprouting. Appositional healing to spare spinal cord tissue, decreased post-traumatic cyst formation, and decreased spinal cord tissue pressure have been demonstrated in preclinical models of spinal cord contusion injury. The Neuro-Spinal Scaffold, an investigational device, has received a Humanitarian Use Device (HUD) designation and is currently being studied in an Investigational Device Exemption (IDE) pilot study for the treatment of patients with complete (AIS A) traumatic acute spinal cord injury.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. In 2011, the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. In 2015, the company’s investigational Neuro-Spinal Scaffold received the 2015 Becker’s Healthcare Spine Device Award. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as “believe,” “anticipate,” “intend,” “estimate,” “will,” “may,” “should,” “expect,” “designed to,” “potentially,” and similar expressions, and include statements regarding continued enrollment in our pilot trial and the expected benefits, efficacy and future clinical outcomes of the company’s Neuro-Spinal Scaffold. Any forward-looking statements contained herein are based on current expectations, and are subject to a number of risks and uncertainties. Factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the company’s ability to successfully open additional clinical sites for enrollment and to enroll additional patients; the timing of the Institutional Review Board process; the company’s ability to obtain FDA approval to modify its pilot trial protocol or to conduct a future study; the company’s ability to commercialize its products; the company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the company’s products and technology in connection with the treatment of spinal cord injuries; the availability of substantial additional funding for the company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and other risks associated with the company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies identified and described in more detail in the company’s Annual Report on Form 10-K for the year ended December 31, 2014, and its other filings with the SEC, including the company’s Form 10-Qs and current reports on Form 8-K. The company does not undertake to update these forward-looking statements.

(MARA) Subsidiary Enters Into Settlement and License Agreement With Ricoh